US-based pre-clinical and clinical laboratory services provider Charles River Laboratories International has extended its drug discovery alliance with Roche Group’s Genentech.
As part of the integrated alliance, Charles River will provide early discovery services including medicinal chemistry, in vitro and in vivo biology, structural biology, and computer-aided drug design to Genentech.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
These services will help Genentech identify promising candidates for preclinical development.
Charles River Laboratories International Integrated Drug Discovery executive director John Montana said: “We are proud to work with Genentech to identify early-stage molecules that will ultimately result in innovative treatments for patients.
“Our long-term collaboration with Genentech has been mutually beneficial for both companies. As our teams have demonstrated, when biotechs and CROs work together, they have the ability to enhance innovations in early discovery research.”
Charles River and Genentech have engaged in an ongoing programme since 2005. The latest extension of the drug discovery alliance will allow the programme to continue for another three years.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataStarting with a single project involving medicinal chemistry, the programme has evolved over the past 11 years to a multi-disciplinary collaboration.
Global pharmaceutical and biotechnology companies, government agencies, and academic institutions use Charles River’s products and services to accelerate their research and drug development efforts.
